The Dosage and Administration section has been revised to state that Mavyret is recommended for 12 weeks in liver or kidney transplant recipients. The Food and Drug Administration (FDA) has approved ...

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mavyret demonstrated 97% sustained virologic response in ...

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. Glecaprevir, one of the two DAAs in Mavyret, was Discovered ...

AbbVie’s hepatitis C blockbuster Mavyret could soon also be an eight-week treatment for patients with compensated cirrhosis, thanks to positive new phase 3b data. That would give it more firepower as ...

AbbVie has received the Food and Drug Administration’s nod for a new indication for Mavyret (glecaprevir and pibrentasvir) tablets for an eight-week duration for the treatment of adults and children ...

AbbVie Inc. ( ABBV) has received approval from the U.S. Food and Drug Administration for the commercialization of its Mavyret, according to the organization. Mavyret is the brand name under which the ...

Please provide your email address to receive an email when new articles are posted on . The approval allows for immediate treatment following diagnosis. Patients treated in a phase 3 study experienced ...

HCV is a curable condition, but patients can often go undiagnosed. 1 If left untreated, people with acute HCV could progress to chronic disease, including liver-related complications, such as ...

Gilead Sciences' once-high-flying hepatitis C drugs have come a long way down since their peak sales years, but thanks to new competition from AbbVie, the company's important franchise will have ...

Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes ...